Screener
Royalty Pharma RPRX Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:NotesAndLoansReceivableNetNoncurrent.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Other royalty income receivable | 31,474 | 29,316 |
| Other current assets | 6,656 | 6,893 |
| Total current assets | 1,764,570 | 1,528,091 |
| Financial royalty assets, net | 16,192,717 | 16,208,482 |
| Equity securities | 241,918 | 171,312 |
| Available for sale debt securities | 372,100 | 419,000 |
| Equity method investments | 261,973 | 289,968 |
| Goodwill | 923,535 | 924,634 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's other non-current assets?
- Royalty Pharma (RPRX) reported other non-current assets of $16.19B in Q2 2026.
- How has Royalty Pharma's other non-current assets changed year-over-year?
- Royalty Pharma's other non-current assets increased by 7.0% year-over-year, from $15.13B to $16.19B.
- What is the long-term trend for Royalty Pharma's other non-current assets?
- Over 5 years (2020 to 2025), Royalty Pharma's other non-current assets has grown at a 5.6% compound annual growth rate (CAGR), from $12.37B to $16.21B.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.
Ask your AI about Royalty Pharma's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude